Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA.
J Control Release. 2011 Dec 10;156(2):128-45. doi: 10.1016/j.jconrel.2011.07.002. Epub 2011 Jul 6.
Despite the fact that we live in an era of advanced and innovative technologies for elucidating underlying mechanisms of diseases and molecularly designing new drugs, infectious diseases continue to be one of the greatest health challenges worldwide. The main drawbacks for conventional antimicrobial agents are the development of multiple drug resistance and adverse side effects. Drug resistance enforces high dose administration of antibiotics, often generating intolerable toxicity, development of new antibiotics, and requests for significant economic, labor, and time investments. Recently, nontraditional antibiotic agents have been of tremendous interest in overcoming resistance that is developed by several pathogenic microorganisms against most of the commonly used antibiotics. Especially, several classes of antimicrobial nanoparticles (NPs) and nanosized carriers for antibiotics delivery have proven their effectiveness for treating infectious diseases, including antibiotics resistant ones, in vitro as well as in animal models. This review summarizes emerging efforts in combating against infectious diseases, particularly using antimicrobial NPs and antibiotics delivery systems as new tools to tackle the current challenges in treating infectious diseases.
尽管我们生活在一个先进和创新技术的时代，可以阐明疾病的潜在机制并分子设计新药物，但传染病仍然是全球面临的最大健康挑战之一。传统抗菌药物的主要缺点是产生多种耐药性和不良反应。耐药性要求高剂量使用抗生素，这往往会产生无法忍受的毒性，需要开发新的抗生素，并要求大量的经济、劳动力和时间投入。最近，非传统抗生素在克服几种致病微生物对大多数常用抗生素产生的耐药性方面引起了极大的关注。特别是，几类抗菌纳米粒子（NPs）和抗生素递送的纳米载体已被证明在体外和动物模型中对治疗传染病，包括抗生素耐药性传染病，具有有效性。本综述总结了在对抗传染病方面的新进展，特别是使用抗菌 NPs 和抗生素递药系统作为新工具来应对治疗传染病方面的当前挑战。
